Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study).

Date publication

juillet 2017

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28738258

Résumé

We evaluated the role of bevacizumab as part of the multi-modality treatment of children and adolescents with metastatic rhabdomyosarcoma (RMS) or non-rhabdomyosarcoma soft tissue sarcoma (NRSTS).

Mots clés

Bevacizumab, Metastatic soft tissue sarcoma, NRSTS, Paediatrics, RMS

Référence

Eur. J. Cancer. 2017 Jul;83:177-184